Seattle Genetics' Adcetris sales fall short yet again

Seattle Genetics's stock fell 5% Friday after the biotech reported sales that once again fell below Wall Street forecasts.
While the company's sole marketed product, the cancer drug Adcetris, is still growing, quarterly sales have missed Wall Street forecasts for three consecutive quarters, noted SVB Leerink analyst Andrew Berens. For the first three months of 2019, the drug posted $135 million in sales, up just 2% from the three month period ending in December.